Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
232
NCT03950570
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: May 25, 2019
Completion: Jan 30, 2023
NCT05154201
Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.
Start: Jul 1, 2020
Completion: Jan 30, 2025
NCT04643769
Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase: Phase 1
Start: Feb 9, 2021
Completion: Dec 30, 2025